GleamWall
中文EN

LXRX LEXICON PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1062822 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-45.6%
TTM net income YoY9.1%
TTM EPS YoY21.1%
Revenue 3-yr CAGR317.1%
Net income 3-yr CAGR—

Margins

Gross margin98.9%
Operating margin-147.4%
Net margin-161.8%
FCF margin—
EBITDA margin-146.3%

Returns

ROE-43.9%
ROA-27.8%
ROIC (approx.)-33.3%
Asset turnover0.17x

Leverage & solvency

Liabilities / assets32.3%
Debt / equity0.32x
Current ratio10.63x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$11.25M$692,000$21.10M$5.49M$14.18M$28.87M$1.26M$26.55M
Cost of revenue$79,000$39,000$108,000$201,000$10,000$33,000$30,000$348,000
Gross profit$11.17M$653,000$20.99M$5.29M$14.17M$28.83M$1.23M$26.21M
R&D expense$16.20M$17.44M$12.76M$11.31M$18.76M$15.75M$15.30M$26.68M
SG&A expense$9.46M$9.75M$9.23M$8.76M$7.60M$9.35M$11.61M$32.26M
Operating income-$14.49M-$26.54M-$996,000-$14.78M-$12.19M$3.74M-$25.68M-$32.74M
Net income-$14.01M-$31.77M-$1.04M-$15.53M-$12.77M$3.25M-$25.30M-$33.77M
EBITDA-$14.40M-$26.44M-$886,000-$14.66M-$12.04M$3.91M-$25.50M-$32.61M
EPS (basic)-0.03-0.070.00—-0.040.01-0.07—
EPS (diluted)-0.03-0.070.00—-0.040.01-0.07—
Weighted avg. shares (diluted)444.96M437.65M400.24M—363.40M363.57M362.07M—
Balance sheet
Cash & equivalents$44.08M$40.92M$38.09M$34.33M$78.66M$50.36M$62.89M$66.66M
Short-term investments$139.12M$149.69M$132.57M$61.90M$66.29M$117.64M$131.95M$171.30M
Receivables$1.78M$1.64M$11.78M$2.38M$2.33M$2.18M$47.45M$3.47M
Inventory$1.21M$1.20M$276,000$281,000$158,000$168,000$201,000$231,000
Current assets$188.84M$196.58M$186.03M$101.89M$122.53M$145.08M$245.81M$246.19M
PP&E, net$1.56M$1.65M$1.75M$1.86M$1.98M$2.13M$2.31M$2.48M
Goodwill$44.54M$44.54M$44.54M$44.54M$44.54M$44.54M$44.54M$44.54M
Total assets$242.02M$250.06M$268.82M$184.99M$205.93M$225.58M$297.67M$298.42M
Current liabilities$17.77M$14.71M$9.90M$20.87M$21.72M$34.84M$110.69M$45.25M
Short-term debt$0$0$0$4.59M——$42.06M$0
Long-term debt$51.89M$51.44M$49.68M$49.41M$56.51M$56.11M$58.64M$100.30M
Total debt$51.89M$51.44M$49.68M$54.00M$56.51M$56.11M$100.70M$100.30M
Total liabilities$78.18M$75.53M$65.96M$77.45M$85.77M$96.14M$174.64M$152.47M
Shareholders' equity$163.84M$174.53M$202.86M$107.54M$120.16M$129.44M$123.03M$145.95M
Net debt$7.81M$10.51M$11.60M$19.68M-$22.15M$5.74M$37.81M$33.64M
Shares outstanding446.91M446.87M425.71M365.85M365.78M——363.02M
Cash flow statement
Operating cash flow-$8.08M-$9.19M-$14.73M-$17.23M-$23.83M$16.99M-$43.78M-$21.49M
Capital expenditure———$0$0——$474,000
Free cash flow———-$17.23M-$23.83M——-$21.96M
Investing cash flow$11.18M-$16.46M-$70.26M$4.83M$52.12M$15.48M$40.58M$53.70M
Financing cash flow$55,000-$512,000$88.76M-$2.93M$0-$45.00M-$572,000-$104,000
Depreciation & amortization$95,000$102,000$110,000$118,000$151,000$176,000$176,000$125,000
Stock-based compensation$3.40M$3.30M$3.08M$2.83M$3.40M$3.20M$3.04M$1.54M
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.